Intratech Medical’s Booster Coronary Sinus Spiral Balloon Therapy Evaluated for AMI in First-in-Human Study

July 13, 2022—Intratech Medical announced the commencement of enrollment with two patients in a multicenter, first-in-human study assessing the safety and technical performance of the company’s Booster spiral balloon therapy in the treatment of patients undergoing coronary catheterization after acute myocardial infarction (AMI). With its spiral design, the balloon is intended to minimize infarct size growth by elevating pressure in the heart’s vasculature.

According to the company, the Booster balloon is placed in the coronary sinus immediately after revascularization of the clogged artery. The Booster spiral balloon causes temporary restriction of blood outflow, which elevates the vascular pressure without compromising the blood outflow. This elevated pressure improves oxygen delivery to the ischemic myocardium, reducing the infarct area and ultimately improving patient outcomes.

Irakli Gogorishvili, MD, who is Head of the Cardiology Department at the Helsicore Medical Center in Tbilisi, Georgia, and Principal Investigator of the study, commented in the company’s press release, “We hope that the Booster therapy will help to improve clinical outcomes of patients undergoing AMI. The first two cases were very successful—no learning curve is needed, it’s a very user-friendly device, and we are confident to perform more cases.”